Compare · BBNX vs BSX
BBNX vs BSX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 83.0x BBNX ($870.1M).
- Over the past year, BBNX is up 5.5% and BSX is down 53.1% - BBNX leads by 58.6 points.
- BSX has been more active in the news (10 items in the past 4 weeks vs 2 for BBNX).
- BSX has more recent analyst coverage (25 ratings vs 18 for BBNX).
- Company
- Beta Bionics Inc.
- Boston Scientific Corporation
- Price
- $19.33-2.13%
- $49.86+1.73%
- Market cap
- $870.1M
- $72.26B
- 1M return
- +20.81%
- +9.58%
- 1Y return
- +5.46%
- -53.13%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 2
- 10
- Recent ratings
- 18
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BBNX
- William Blair initiated coverage on Beta Bionics
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
- UBS resumed coverage on Beta Bionics with a new price target
- Amendment: Chief Financial Officer Feider Stephen exercised 10,000 shares at a strike of $5.10 and sold $170,387 worth of shares (10,000 units at $17.04) as part of a pre-agreed trading plan (SEC Form 4)
- Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
- Chief Financial Officer Feider Stephen exercised 9,878 shares at a strike of $5.10 and sold $170,387 worth of shares (10,000 units at $17.04) as part of a pre-agreed trading plan, decreasing direct ownership by 0.07% to 165,931 units (SEC Form 4)
- Chief Commercial Officer Hopman Mark sold $18,880 worth of shares (1,258 units at $15.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.96% to 129,354 units (SEC Form 4)
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation